Unfortunately there are still a large number of people dying of COVID-19 <65 years old according to CDC records in the USA... and it is unknown if an increased dose of Remestemcel-L will in fact help patients older than 65 but at least they should give that a try IMO .....
An additional COVID-19 ARDS trial could be split with an <65yo cohort and an >65yo cohort with an increased dose for the latter to see what transpires ?
Many on here who say stems are too expensive or are not the answer obviously are ok with hundreds of thousands of people under 65 dying of COVID-19 while at the same time failing to recognise the extraordinary costs associated with end of life in ICU for COVID-19 victims or the fact that death is absolute .... [shakes head]
GLTAH
https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#AgeAndSex
![]()
- Forums
- ASX - By Stock
- MSB
- RWE for 2nd MSB COVID-19 ARDS P3 Trial
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-92
-
- There are more pages in this discussion • 814 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 8683 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 32999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8683 | 1.155 |
7 | 295447 | 1.150 |
3 | 70786 | 1.145 |
6 | 196386 | 1.140 |
3 | 75486 | 1.135 |
Price($) | Vol. | No. |
---|---|---|
1.165 | 32999 | 1 |
1.170 | 62618 | 6 |
1.175 | 48590 | 3 |
1.180 | 79079 | 4 |
1.185 | 17090 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online